Paulo Fonseca
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Paulo Fonseca has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Helena Gonçalves
Department of Cardiology, Gaia Hospital Center , Rua Conceição Fernandes, 4434-502 Vila Nova de Gaia
7 shared publicationsVasco Gama
Serviço de Cardiologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
6 shared publications- Nuno Bettencourt
Universidade do Porto, Portugal
4 shared publications Francisco Sampaio
Department of Cardiology, Vila Nova de Gaia Hospital Center, Vila Nova de Gaia, Portugal
3 shared publicationsJosé Ribeiro
Serviço de Cardiologia, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
3 shared publications- João Primo
Cardiology Department, Hospital da Luz Arrábida , Porto
3 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
A Practical, Physiology-Guided Approach to Cardioneuroablation for Vagally Mediated Bradyarrhythmias
Aims: Cardioneuroablation (CNA) attenuates excessive parasympathetic input to the sinus and atrioventricular (AV) nodes by ablating atrial ganglionated plexi (GP), while preserving sympathetic innervation and intrinsic nodal function. It offers a mechanism-directed alternative to permanent pacing in selected patients with reflex syncope, functional AV block, or symptomatic vagally mediated sinus bradycardia. This review translates that physiological rationale into a practical, reproducible procedural framework. Methods and Results: Current evidence is synthesised with the collective procedural experience of the writing group. Successful implementation rests on careful patient selection, accurate identification of the cardioinhibitory phenotype, and a structured, physiology-guided procedure. Implantable loop recorders are central to documenting spontaneous events and distinguishing sinus- from AV-nodal mechanisms, complemented by tilt-table and atropine testing. During ablation, extracardiac vagal stimulation (ECVS) provides the most robust physiological endpoint for confirming vagal attenuation; where ECVS is unavailable, surrogate markers can guide the procedure, albeit with recognised limitations. Practical workflows are set out, including phenotype-driven GP targeting, the ablate–test–ablate sequence, and distinct strategies for sinus-node– and AV-node–predominant phenotypes. Technical considerations, safety, laterality of ablation, and challenging scenarios—recurrence after apparently successful CNA, athletes with functional bradyarrhythmias, and CNA during atrial fibrillation ablation—are also addressed. Conclusion: By emphasising procedural implementation and physiological endpoints, and situating CNA within the broader management of vagally mediated bradyarrhythmias, this review offers a reproducible, phenotype-guided framework to support its safe and effective use. It reflects current evidence and accumulated procedural experience rather than formal recommendation.
- 13 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal Open
Open AccessA Practical, Physiology-Guided Approach to Cardioneuroablation for Vagally Mediated Bradyarrhythmias
Aims: Cardioneuroablation (CNA) attenuates excessive parasympathetic input to the sinus and atrioventricular (AV) nodes by ablating atrial ganglionated plexi (GP), while preserving sympathetic innervation and intrinsic nodal function. It offers a mechanism-directed alternative to permanent pacing in selected patients with reflex syncope, functional AV block, or symptomatic vagally mediated sinus bradycardia. This review translates that physiological rationale into a practical, reproducible procedural framework. Methods and Results: Current evidence is synthesised with the collective procedural experience of the writing group. Successful implementation rests on careful patient selection, accurate identification of the cardioinhibitory phenotype, and a structured, physiology-guided procedure. Implantable loop recorders are central to documenting spontaneous events and distinguishing sinus- from AV-nodal mechanisms, complemented by tilt-table and atropine testing. During ablation, extracardiac vagal stimulation (ECVS) provides the most robust physiological endpoint for confirming vagal attenuation; where ECVS is unavailable, surrogate markers can guide the procedure, albeit with recognised limitations. Practical workflows are set out, including phenotype-driven GP targeting, the ablate–test–ablate sequence, and distinct strategies for sinus-node– and AV-node–predominant phenotypes. Technical considerations, safety, laterality of ablation, and challenging scenarios—recurrence after apparently successful CNA, athletes with functional bradyarrhythmias, and CNA during atrial fibrillation ablation—are also addressed. Conclusion: By emphasising procedural implementation and physiological endpoints, and situating CNA within the broader management of vagally mediated bradyarrhythmias, this review offers a reproducible, phenotype-guided framework to support its safe and effective use. It reflects current evidence and accumulated procedural experience rather than formal recommendation.
- Open Access
- 7 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (6) , 1181-1193
Predicting patient-related outcomes after atrial fibrillation ablation: insights from explainable artificial intelligence and digital health
Aims: Quality of life (QoL) improvement is a primary driver for atrial fibrillation (AF) catheter ablation (CA), yet its determinants remain unclear. We aimed to identify patient phenotypes with distinct post-ablation QoL trajectories, determine their key predictors, and clarify their association with arrhythmia recurrence and reintervention. Methods and results: We prospectively followed 213 patients (median age 60 years, 31% female) undergoing AF CA at a tertiary hospital for 2.2 years [interquartile range (IQR): 1.6–2.6]. A digital health application collected real-time electronic patient-reported outcomes (PROs), including the AF Effect on QoL (AFEQT) questionnaire. Reference charts were generated from QoL trajectories of recurrence-free patients. Machine learning (ML) identified subgroups with distinct QoL trajectories, and explainable artificial intelligence (AI) highlighted key predictors. Quality of life improved by +26 AFEQT points [95% confidence interval (CI): 18–33] within 3 months post-ablation and remained stable thereafter, despite significant heterogeneity in individual responses. Patients with AF recurrence showed significantly lower QoL gains (P = 0.010). Machine learning identified three phenotypes: a younger cluster with the largest QoL improvements, an emotive cluster with higher recurrence rates and minimal QoL benefits despite additional antiarrhythmic reinterventions, and an older cluster with established cardiovascular risk factors. Anxiety, age, and AF duration emerged as key discriminators. Conclusion: ML defined three clinically coherent phenotypes, each exhibiting distinct QoL trajectories and ablation outcomes. Explainable AI clarified how individual psychological and biological traits interact to shape these outcomes, highlighting the potential for tailored multidisciplinary care beyond individualized rhythm control strategies.
- 7 August 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Digital Health
- Vol. 6 (6) , 1181-1193
Open AccessPredicting patient-related outcomes after atrial fibrillation ablation: insights from explainable artificial intelligence and digital health
Aims: Quality of life (QoL) improvement is a primary driver for atrial fibrillation (AF) catheter ablation (CA), yet its determinants remain unclear. We aimed to identify patient phenotypes with distinct post-ablation QoL trajectories, determine their key predictors, and clarify their association with arrhythmia recurrence and reintervention. Methods and results: We prospectively followed 213 patients (median age 60 years, 31% female) undergoing AF CA at a tertiary hospital for 2.2 years [interquartile range (IQR): 1.6–2.6]. A digital health application collected real-time electronic patient-reported outcomes (PROs), including the AF Effect on QoL (AFEQT) questionnaire. Reference charts were generated from QoL trajectories of recurrence-free patients. Machine learning (ML) identified subgroups with distinct QoL trajectories, and explainable artificial intelligence (AI) highlighted key predictors. Quality of life improved by +26 AFEQT points [95% confidence interval (CI): 18–33] within 3 months post-ablation and remained stable thereafter, despite significant heterogeneity in individual responses. Patients with AF recurrence showed significantly lower QoL gains (P = 0.010). Machine learning identified three phenotypes: a younger cluster with the largest QoL improvements, an emotive cluster with higher recurrence rates and minimal QoL benefits despite additional antiarrhythmic reinterventions, and an older cluster with established cardiovascular risk factors. Anxiety, age, and AF duration emerged as key discriminators. Conclusion: ML defined three clinically coherent phenotypes, each exhibiting distinct QoL trajectories and ablation outcomes. Explainable AI clarified how individual psychological and biological traits interact to shape these outcomes, highlighting the potential for tailored multidisciplinary care beyond individualized rhythm control strategies.
- Open Access
- 2 June 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (6)
Ostial vs. wide area circumferential ablation guided by the Ablation Index in paroxysmal atrial fibrillation
Pulmonary vein isolation (PVI) guided by the Ablation Index (AI) has shown high acute and mid-term efficacy in the treatment of paroxysmal atrial fibrillation (AF). Previous data before the AI-era had suggested that wide-area circumferential ablation (WACA) was preferable to ostial ablation. However, with the use of AI, we hypothesize that ostial circumferential ablation is non-inferior to WACA and can improve outcomes in paroxysmal AF. Prospective, multicentre, non-randomized, non-inferiority study of consecutive patients were referred for paroxysmal AF ablation from January 2020 to September 2021. All procedures were performed using the AI software, and patients were separated into two different groups: WACA vs. ostial circumferential ablation. Acute reconnection, procedural data, and 1-year arrhythmia recurrence were assessed. During the enrolment period, 162 patients (64% males, mean age of 60 ± 11 years) fulfilled the study inclusion criteria—81 patients [304 pulmonary vein (PV)] in the WACA group and 81 patients (301 PV) in the ostial group. Acute PV reconnection was identified in 7.9% [95% confidence interval (CI), 4.9–11.1%] of PVs in the WACA group compared with 3.3% (95% CI, 1.8–6.1%) of PVs in the ostial group [P < 0.001 for non-inferiority; adjusted odds ratio 0.51 (95% CI, 0.23–0.83), P = 0.05]. Patients in the WACA group had longer ablation (35 vs. 29 min, P = 0.001) and procedure (121 vs. 102 min, P < 0.001) times. No significant difference in arrhythmia recurrence was seen at 1-year of follow-up [11.1% in WACA vs. 9.9% in ostial, hazard ratio 1.13 (95% CI, 0.44–1.94), P = 0.80 for superiority]. In paroxysmal AF patients treated with tailored AI-guided PVI, ostial circumferential ablation is not inferior to WACA with regard to acute PV reconnection, while allowing quicker procedures with less ablation time. Distribution of acute pulmonary vein reconnection in both groups [wide-area circumferential ablation (WACA) vs. ostial] (central panel), with an illustration of the typical location for ablation lines in each corresponding group, in a posterior view (left panel). Ostial ablation was not inferior to WACA with regard to acute pulmonary vein reconnections (P < 0.001 for non-inferiority; P = 0.05 adjusted for superiority) and arrhythmia recurrence at 1-year of follow-up (P < 0.001 for non-inferiority; P = 0.80 for superiority), while requiring less ablation (P = 0.001) and allowing for quicker procedures (P < 0.001) (right panel).
- 2 June 2023
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 25 (6)
Open AccessOstial vs. wide area circumferential ablation guided by the Ablation Index in paroxysmal atrial fibrillation
Pulmonary vein isolation (PVI) guided by the Ablation Index (AI) has shown high acute and mid-term efficacy in the treatment of paroxysmal atrial fibrillation (AF). Previous data before the AI-era had suggested that wide-area circumferential ablation (WACA) was preferable to ostial ablation. However, with the use of AI, we hypothesize that ostial circumferential ablation is non-inferior to WACA and can improve outcomes in paroxysmal AF. Prospective, multicentre, non-randomized, non-inferiority study of consecutive patients were referred for paroxysmal AF ablation from January 2020 to September 2021. All procedures were performed using the AI software, and patients were separated into two different groups: WACA vs. ostial circumferential ablation. Acute reconnection, procedural data, and 1-year arrhythmia recurrence were assessed. During the enrolment period, 162 patients (64% males, mean age of 60 ± 11 years) fulfilled the study inclusion criteria—81 patients [304 pulmonary vein (PV)] in the WACA group and 81 patients (301 PV) in the ostial group. Acute PV reconnection was identified in 7.9% [95% confidence interval (CI), 4.9–11.1%] of PVs in the WACA group compared with 3.3% (95% CI, 1.8–6.1%) of PVs in the ostial group [P < 0.001 for non-inferiority; adjusted odds ratio 0.51 (95% CI, 0.23–0.83), P = 0.05]. Patients in the WACA group had longer ablation (35 vs. 29 min, P = 0.001) and procedure (121 vs. 102 min, P < 0.001) times. No significant difference in arrhythmia recurrence was seen at 1-year of follow-up [11.1% in WACA vs. 9.9% in ostial, hazard ratio 1.13 (95% CI, 0.44–1.94), P = 0.80 for superiority]. In paroxysmal AF patients treated with tailored AI-guided PVI, ostial circumferential ablation is not inferior to WACA with regard to acute PV reconnection, while allowing quicker procedures with less ablation time. Distribution of acute pulmonary vein reconnection in both groups [wide-area circumferential ablation (WACA) vs. ostial] (central panel), with an illustration of the typical location for ablation lines in each corresponding group, in a posterior view (left panel). Ostial ablation was not inferior to WACA with regard to acute pulmonary vein reconnections (P < 0.001 for non-inferiority; P = 0.05 adjusted for superiority) and arrhythmia recurrence at 1-year of follow-up (P < 0.001 for non-inferiority; P = 0.80 for superiority), while requiring less ablation (P = 0.001) and allowing for quicker procedures (P < 0.001) (right panel).
- 13 July 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 22 (3) , e4
Atrial tachycardia from aneurysmatic left atrial appendage
A 45-year-old woman with no significant past medical history was referred to our centre due to a recurrent symptomatic atrial tachycardia (AT) with 2:1 atrioventricular conduction (Panel A), refractory to antiarrhythmics. Transthoracic echocardiogram was unremarkable with normal atrial dimensions. She was referred for electrophysiological study (EPS) aiming AT mapping and ablation. Before the procedure, she underwent cardiac 128-slice multi-detector computed tomography that showed the presence of a giant left atrial appendage (LAA) with an estimated volume of 77 mL (Panels B and C). During EPS, an AT (cycle length of 320 ms) was induced (Panel D) and activation map using a multipolar...
- 13 July 2020
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 22 (3) , e4
Atrial tachycardia from aneurysmatic left atrial appendage
A 45-year-old woman with no significant past medical history was referred to our centre due to a recurrent symptomatic atrial tachycardia (AT) with 2:1 atrioventricular conduction (Panel A), refractory to antiarrhythmics. Transthoracic echocardiogram was unremarkable with normal atrial dimensions. She was referred for electrophysiological study (EPS) aiming AT mapping and ablation. Before the procedure, she underwent cardiac 128-slice multi-detector computed tomography that showed the presence of a giant left atrial appendage (LAA) with an estimated volume of 77 mL (Panels B and C). During EPS, an AT (cycle length of 320 ms) was induced (Panel D) and activation map using a multipolar...
- Open Access
- 1 October 2017
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 36 (10) , 747-753
Incidence and predictors of vascular access site complications following transfemoral transcatheter aortic valve implantation
- 1 October 2017
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 36 (10) , 747-753
Open AccessIncidence and predictors of vascular access site complications following transfemoral transcatheter aortic valve implantation
- 5 January 2016
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 29 (1) , 117-123
Aortic Valve Calcium Volume Predicts Paravalvular Regurgitation and the Need for Balloon Post‐Dilatation After Transcatheter Aortic Valve Implantation
Objective: This study sought to evaluate the impact of aortic valve (AV) and left ventricle outflow tract (LVOT) calcium on paravalvular regurgitation (PVR) and need for balloon post‐dilatation (BPD) during transcatheter aortic valve implantation (TAVI).Methods: The overall study population comprised 152 patients. Calcium mass and volume of AV and LVOT were estimated from contrast‐enhanced multislice computed tomography imaging, using 3 thresholds for calcium detection [650, 850, and 1,050 Hounsfield units (HU)].Results: A self‐expandable prosthesis was implanted in 67.8% of patients and a balloon‐expandable prosthesis in the remaining. Eleven patients required BPD and 82 patients presented post‐procedural PVR, which was mild in 44.1% and moderate in 9.9%. The greatest discriminatory value for PVR ≥ mild was seen for calcium volume using 850 HU threshold, with an area under the curve of 0.72 (95%CI 0.64–0.80, P < 0.001) for AV and of 0.63 (95%CI 0.54–0.72, P = 0.008) for LVOT. For 850 HU threshold, the calcium volume cut‐off with the highest sum of sensitivity and specificity for PVR was 157 mm3 for AV and 0.6 mm3 for LVOT. In multivariate logistic regression analysis, the presence of AV calcium ≥157 mm3 (OR 3.83, 95%CI 1.81–8.10, P < 0.001) and ≥267 mm3 (OR 11.3, 95%CI 1.2–103.1, P = 0.03) were the only independent predictors of PVR and BPD, respectively.Conclusions: AV calcium volume was an independent predictor of PVR and BPD in patients submitted to TAVI. Our results support a systematic assessment of AV calcium volume to identify patients at increased risk of post‐procedural PVR. (J Interven Cardiol 2016;29:117–123)
- 5 January 2016
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 29 (1) , 117-123
Aortic Valve Calcium Volume Predicts Paravalvular Regurgitation and the Need for Balloon Post‐Dilatation After Transcatheter Aortic Valve Implantation
Objective: This study sought to evaluate the impact of aortic valve (AV) and left ventricle outflow tract (LVOT) calcium on paravalvular regurgitation (PVR) and need for balloon post‐dilatation (BPD) during transcatheter aortic valve implantation (TAVI).Methods: The overall study population comprised 152 patients. Calcium mass and volume of AV and LVOT were estimated from contrast‐enhanced multislice computed tomography imaging, using 3 thresholds for calcium detection [650, 850, and 1,050 Hounsfield units (HU)].Results: A self‐expandable prosthesis was implanted in 67.8% of patients and a balloon‐expandable prosthesis in the remaining. Eleven patients required BPD and 82 patients presented post‐procedural PVR, which was mild in 44.1% and moderate in 9.9%. The greatest discriminatory value for PVR ≥ mild was seen for calcium volume using 850 HU threshold, with an area under the curve of 0.72 (95%CI 0.64–0.80, P < 0.001) for AV and of 0.63 (95%CI 0.54–0.72, P = 0.008) for LVOT. For 850 HU threshold, the calcium volume cut‐off with the highest sum of sensitivity and specificity for PVR was 157 mm3 for AV and 0.6 mm3 for LVOT. In multivariate logistic regression analysis, the presence of AV calcium ≥157 mm3 (OR 3.83, 95%CI 1.81–8.10, P < 0.001) and ≥267 mm3 (OR 11.3, 95%CI 1.2–103.1, P = 0.03) were the only independent predictors of PVR and BPD, respectively.Conclusions: AV calcium volume was an independent predictor of PVR and BPD in patients submitted to TAVI. Our results support a systematic assessment of AV calcium volume to identify patients at increased risk of post‐procedural PVR. (J Interven Cardiol 2016;29:117–123)
- Open Access
- 1 December 2015
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 34 (12) , 713-718
Appropriate use criteria for transthoracic echocardiography at a tertiary care center
- 1 December 2015
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 34 (12) , 713-718
Open AccessAppropriate use criteria for transthoracic echocardiography at a tertiary care center
- Open Access
- 17 November 2015
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 17 (2) , 153
A familial cluster of left ventricular non-compaction and mitral valve prolapse
We report the cases of concomitant left ventricular non-compaction (LVNC) and mitral valve prolapse in two adult siblings. The first patient was a 41-year-old woman who was referred to our centre due to suspected LVNC. Transthoracic echocardiography showed moderate dilation of the left atrium and left ventricle, hypertrabeculated myocardium and mitral valve prolapse with severe eccentric mitral regurgitation ( Panels A and B ; Supplementary data online, Videos S1–S3 ). Cardiac magnetic resonance confirmed the diagnosis of LVNC ( Panel C ; Supplementary data online, Video S4 ). Genetic testing revealed a heterozygous mutation in the TNNT2 gene (c.115G > A). Her 44-year-old brother presented a similar phenotype with LVNC associated with anterior mitral valve leaflet prolapse causing severe mitral regurgitation ( Panel D ; Supplementary data online, Videos S5 and S6 ). Both atria were severely dilated, and the left ventricle was moderately dilated with preserved systolic function. He refused to perform genetic testing. There was family history of cardiomyopathy in other siblings; however, additional clinical information was not available.
- 17 November 2015
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 17 (2) , 153
Open AccessA familial cluster of left ventricular non-compaction and mitral valve prolapse
We report the cases of concomitant left ventricular non-compaction (LVNC) and mitral valve prolapse in two adult siblings. The first patient was a 41-year-old woman who was referred to our centre due to suspected LVNC. Transthoracic echocardiography showed moderate dilation of the left atrium and left ventricle, hypertrabeculated myocardium and mitral valve prolapse with severe eccentric mitral regurgitation ( Panels A and B ; Supplementary data online, Videos S1–S3 ). Cardiac magnetic resonance confirmed the diagnosis of LVNC ( Panel C ; Supplementary data online, Video S4 ). Genetic testing revealed a heterozygous mutation in the TNNT2 gene (c.115G > A). Her 44-year-old brother presented a similar phenotype with LVNC associated with anterior mitral valve leaflet prolapse causing severe mitral regurgitation ( Panel D ; Supplementary data online, Videos S5 and S6 ). Both atria were severely dilated, and the left ventricle was moderately dilated with preserved systolic function. He refused to perform genetic testing. There was family history of cardiomyopathy in other siblings; however, additional clinical information was not available.
- Open Access
- 6 March 2015
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 16 (6) , 683
Giant and electrically silent right atrium
A 22-year-old man with no significant past medical history was referred to our centre due to an incessant supraventricular tachycardia with variable atrioventricular conduction and no evidence of sinus rhythm during Holter monitoring. Transthoracic echocardiogram showed a remarkably dilated right atrium and a severe tricuspid regurgitation secondary to annular enlargement (Panels A and B). The tricuspid valve was not displaced, and the right ventricle was slightly dilated with preserved systolic function. Cardiac magnetic resonance imaging confirmed a severe enlargement of right atrium with an estimated volume of 830 mL and excluded other cardiac anomalies (PanelsC and F). He underwent an electrophysiological study that showed an atypical atrial flutter with a cycle length of 254 ms. The sole right atrial electric activity was recorded in the posteroseptal region, with the rest of atrium being inexcitable and devoid of electrogram (PanelsD and E). No ablation was performed due to probable absence of sinus rhythm after tachycardia interruption. He was successfully submitted to an extensive right reduction atrioplasty and a tricuspid valve annuloplasty (PanelG). His post-operative period was uneventful. Histologic examination of the ressected atrial tissue revealed an extreme wall thinning with no other relevant abnormalities (PanelH).
- 6 March 2015
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Imaging
- Vol. 16 (6) , 683
Open AccessGiant and electrically silent right atrium
A 22-year-old man with no significant past medical history was referred to our centre due to an incessant supraventricular tachycardia with variable atrioventricular conduction and no evidence of sinus rhythm during Holter monitoring. Transthoracic echocardiogram showed a remarkably dilated right atrium and a severe tricuspid regurgitation secondary to annular enlargement (Panels A and B). The tricuspid valve was not displaced, and the right ventricle was slightly dilated with preserved systolic function. Cardiac magnetic resonance imaging confirmed a severe enlargement of right atrium with an estimated volume of 830 mL and excluded other cardiac anomalies (PanelsC and F). He underwent an electrophysiological study that showed an atypical atrial flutter with a cycle length of 254 ms. The sole right atrial electric activity was recorded in the posteroseptal region, with the rest of atrium being inexcitable and devoid of electrogram (PanelsD and E). No ablation was performed due to probable absence of sinus rhythm after tachycardia interruption. He was successfully submitted to an extensive right reduction atrioplasty and a tricuspid valve annuloplasty (PanelG). His post-operative period was uneventful. Histologic examination of the ressected atrial tissue revealed an extreme wall thinning with no other relevant abnormalities (PanelH).
- Open Access
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 3 (10) , 900-3
Acute hepatitis after amiodarone infusion
Acute hepatitis is a very rare, but potentially fatal, adverse effect of intravenous amiodarone. We present a case of an 88-year-old man with history of ischemic dilated cardiomyopathy and severely depressed left ventricular function that was admitted to our coronary care unit with diagnosis of decompensated heart failure and non-sustained ventricular tachycardia. A few hours after the beginning of intravenous amiodarone he developed an acute hepatitis. There was a completely recovery within the next days after amiodarone withdrawn and other causes of acute hepatitis have been ruled out. This case highlights the need for close monitoring of hepatic function during amiodarone infusion in order to identify any potential hepatotoxicity and prevent a fatal outcome. Oral amiodarone is, apparently, a safe option in these patients.
- 1 January 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Clinical Cases
- Vol. 3 (10) , 900-3
Open AccessAcute hepatitis after amiodarone infusion
Acute hepatitis is a very rare, but potentially fatal, adverse effect of intravenous amiodarone. We present a case of an 88-year-old man with history of ischemic dilated cardiomyopathy and severely depressed left ventricular function that was admitted to our coronary care unit with diagnosis of decompensated heart failure and non-sustained ventricular tachycardia. A few hours after the beginning of intravenous amiodarone he developed an acute hepatitis. There was a completely recovery within the next days after amiodarone withdrawn and other causes of acute hepatitis have been ruled out. This case highlights the need for close monitoring of hepatic function during amiodarone infusion in order to identify any potential hepatotoxicity and prevent a fatal outcome. Oral amiodarone is, apparently, a safe option in these patients.